Targets › PRKD3
1 program from 1 company in 5 trials: 3 Phase 1, 2 Phase 2; Oncology; next expected readout May 2029.
Converts transient diacylglycerol (DAG) signals into prolonged physiological effects, downstream of PKC. Involved in resistance to oxidative stress (By similarity). (UniProt, O94806)
Open in Phaseline: the race on PRKD3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
Acute Myeloid Leukemia (3) FLT3-mutated Acute Myeloid Leukemia (1) AML/MDS (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.